Investment Summary

Oxford Nanopore Technologies PLC has emerged as one of the most innovative players in the global DNA and RNA sequencing market. Its proprietary nanopore platform offers real-time, scalable, and uniquely portable sequencing solutions that complement and in many cases displace legacy short-read technologies. Strong Demand growth across research, clinical, public health and applied markets, combined with a rapidly expanding installed base and continued technology development, supports a long runway of Revenue growth. Although the company is at an earlier stage of Margin maturation, the trajectory towards scaling profitability is becoming clearer. We rate the shares a Buy on the strength of the differentiated technology platform, expanding applications, growing customer base and meaningful long-term commercial opportunity.

Business Overview

Oxford Nanopore is headquartered in Oxford, United Kingdom, and is listed on the London Stock Exchange. The company develops and sells sequencing devices, flow cells, kits and software that enable rapid, real-time analysis of DNA and RNA. Its technology stack ranges from the handheld MinION, through the benchtop GridION and PromethION, to the high-throughput PromethION 48 platform that competes in the highest-end of the sequencing market. The company also offers the smaller, portable Flongle adapter, the SmidgION ultra-portable concept and the new MinION Mk1D for clinical and field applications.

Customers include academic research institutions, clinical laboratories, pharmaceutical and biotechnology companies, agricultural and environmental organisations, public health agencies and industrial users. Major application areas span human, microbial, plant and animal genomics, infectious disease surveillance, oncology profiling, transcriptomics and epigenetics. The platform is differentiated by its ability to read very long DNA molecules in their native state, in real time, with the option of direct detection of base modifications such as methylation.

Sector Backdrop

The global sequencing market continues to expand rapidly, driven by falling per-base costs, the integration of genomics into clinical decision making, the explosion of omics-based research and the growing role of sequencing in infectious disease surveillance, agriculture and bioindustrial applications. Within the sequencing toolset, long-read approaches such as nanopore are increasingly recognised for their ability to resolve structural variants, repeat regions and complex genomic architectures that are difficult to address with short reads. Real-time sequencing further opens applications such as rapid pathogen identification, contamination monitoring and adaptive sequencing. The COVID-19 Pandemic accelerated genomic surveillance worldwide and increased awareness of the strategic importance of sequencing infrastructure. As global public health systems institutionalise pathogen genomics, and as healthcare systems integrate genomics into clinical workflows, demand for accessible, scalable sequencing platforms is expected to continue growing.

Investment Thesis

There are several elements to our positive view. First, the nanopore platform provides genuine technical differentiation, with capabilities that complement and in many cases substitute for short-read technologies. Second, the company has built a global commercial footprint, supported by direct sales, partner distribution, customer support and a growing installed base of devices. Third, customer applications continue to broaden, with growing penetration in clinical microbiology, infectious disease surveillance, applied biology and pharmaceutical research. Fourth, technological progress continues, with improvements in accuracy, throughput, chemistry and software extending the addressable market further. Fifth, recurring consumables and software revenues represent an increasing proportion of total revenue, providing higher-quality Earnings. Sixth, the Balance Sheet is supported by post-IPO cash reserves, providing flexibility to invest in growth and reach scale. The combination of innovation, growing addressable applications and Recurring Revenue dynamics underpins a long-term compounding profile.

Growth Drivers

Several specific growth drivers reinforce the medium-term outlook. The continued ramp of the high-throughput PromethION platforms is expanding the share of large-scale genomics customers, including population genomics initiatives, biobanks and large research consortia. Clinical applications are growing, with regulatory approvals and quality certifications enabling adoption in infectious disease diagnostics, oncology profiling and other clinical workflows. Public health applications, including pathogen surveillance for influenza, respiratory viruses, antimicrobial resistance and emerging pathogens, are being institutionalised across many countries. Applied markets, including agricultural genomics, food safety, industrial fermentation and environmental DNA, are continuing to expand.

Technical innovation continues to broaden the appeal of the platform. Improvements in raw read accuracy, chemistry advances, the introduction of new sample preparation kits and increasingly powerful bioinformatics software are reducing barriers to adoption. The expansion of duplex sequencing and methylation-aware basecalling addresses important customer needs. Continued growth of consumables revenue, software subscriptions and service contracts is supporting higher-quality and more recurring revenue.

Financial Performance

Oxford Nanopore has delivered strong underlying revenue growth, particularly in the Life Science Research Tools customer segment, which is the company's largest commercial focus. Reported revenues, excluding the unusual COVID-related volumes of the early pandemic period, have continued to grow at attractive double-digit rates. Gross margins have been improving as Manufacturing yields scale, automation extends across the production process and product mix shifts towards higher-margin consumables. Operating losses remain, reflecting continued investment in R&Amp;D, commercialisation and platform development, but management has set a clear pathway towards adjusted EBITDA breakeven and beyond over the medium term. The post-IPO cash position provides multi-year runway to deliver on this trajectory.

Recurring revenue from flow cells, consumables and software is the structural quality lever in the financial model. As the installed base of PromethION, GridION and MinION devices grows, consumables revenue scales in step with customer usage. Software, including the company's EPI2ME bioinformatics platform, is moving towards subscription-based revenue models that should support steady, predictable Cash Flow. The combination of a growing instrument installed base, scaling consumables usage and recurring software revenue is the classic 'razor and blade' model that has historically delivered attractive returns in the life sciences tools industry. As this dynamic plays out, financial performance should become increasingly visible and predictable, supporting both investor confidence and the eventual transition to sustained profitability.

Innovation and Product Roadmap

Continued investment in R&D underpins the future of the platform. The roadmap includes ongoing improvements in nanopore design, basecalling algorithms, sample preparation chemistry and software analytics. Newer instruments such as MinION Mk1D bring clinical-grade capabilities to broader user bases. The company is also developing protein sequencing capabilities, with the potential to extend the platform from nucleic acids into proteomics over time. Investments in cloud-based bioinformatics, integrated data analysis tools and AI-driven applications further enhance the customer experience. The combination of hardware, consumables, software and services provides multiple touchpoints to deepen customer relationships and increase recurring revenue.

Commercialisation Outlook

Commercialisation is supported by a global direct sales force, regional distributors, Customer Service teams and a growing partner ecosystem. The company has established centres of excellence around the world to support customer Training, application development and bioinformatics expertise. Strategic relationships with major research consortia, public health agencies and biopharmaceutical companies are accelerating adoption. The launch of clinical-grade kits, regulatory clearances in key indications and integration with major clinical laboratory workflows are unlocking the clinical market opportunity. As more clinical applications gain regulatory and reimbursement support, the addressable market expands further.

Specific application growth areas include rapid microbial whole genome sequencing for hospital infection prevention and antimicrobial resistance management; cancer profiling for both research and clinical applications; population-scale human genomics initiatives; agricultural genomics covering plant and livestock breeding; and environmental monitoring through metagenomics. Each of these areas represents a meaningful long-term opportunity, supported by growing customer interest, evolving regulatory frameworks and continued technical improvements. The company is also developing programmes around protein sequencing, which would represent a significant new application layer for the platform.

Capital Returns and Capital Structure

Oxford Nanopore is at an investment phase rather than a capital return phase. The post-IPO cash balance is being deployed in R&D, manufacturing scale-up, commercial expansion and selective partnerships. Free cash flow is expected to turn positive as the business scales, at which point capital allocation decisions will broaden to include potential capital returns, additional growth investment or selective M&A. For now, the focus is on delivering scaling profitability while protecting and extending the technological lead.

Valuation Perspective

Oxford Nanopore trades on metrics that reflect its growth potential rather than current profitability, consistent with other innovation-led genomics companies at similar stages of Maturity. Comparison with peers in the broader life science tools and sequencing universe suggests scope for re-rating as the company demonstrates a track record of profitable scaling, expands its clinical footprint and continues to gain share. Long-term discounted cash flow analysis applying conservative growth and margin assumptions points to meaningful upside from current levels. The optionality embedded in additional applications such as protein sequencing further supports the case.

Key Risks

Risks include competitive intensity from established short-read sequencing providers and other long-read entrants, technology execution risk, the timing of profitability, regulatory pathways for clinical applications, customer concentration in selected accounts and macroeconomic exposure to research funding cycles. Currency Volatility, Supply chain reliability for specialised nanopore components and intellectual property protection are also relevant. The company's status as a high-growth, innovation-led name introduces share price volatility that may not suit all investors.

Sustainability and Strategic Outlook

Oxford Nanopore's portable, scalable technology democratises access to genomics, enabling sequencing in field settings, public health laboratories and resource-limited environments. This has profound implications for global health, food security and biodiversity. The company has set environmental targets covering its own operations and supply chain, and increasingly engages with customers on sustainable sequencing workflows. The mission of broadening access to genomic information underpins a credible long-term value creation story aligned with global health and scientific progress.

Technology Differentiation and Competitive Moat

At the heart of Oxford Nanopore's investment thesis is genuine technology differentiation. Unlike sequencing platforms that rely on synthesising new DNA strands, the nanopore platform reads native DNA and RNA molecules directly by measuring changes in ionic current as the molecule passes through a protein nanopore. This unique approach delivers several advantages: very long reads, real-time data generation, direct detection of base modifications and a uniquely scalable form Factor that ranges from a USB-stick device to high-throughput benchtop instruments. The accumulated intellectual property, deep know-how in nanopore engineering, basecalling algorithms and chemistry development creates a meaningful competitive moat. Customers who invest in nanopore workflows develop expertise and infrastructure that further deepens the relationship, supporting recurring consumables revenue.

As the broader sequencing market continues to evolve, the long-read approach is increasingly viewed as complementary to and in many cases superior to short-read sequencing for specific applications. Structural variant detection, complete human genome assembly, microbial whole genome sequencing, rapid clinical microbiology and pathogen surveillance are areas where nanopore has clear advantages. The combination of differentiated technology, growing application breadth and a global commercial footprint supports a strong competitive position over the medium term.

Conclusion: Why We Rate Oxford Nanopore a Buy

Oxford Nanopore Technologies PLC offers an attractive way to invest in long-term genomics demand through a differentiated, real-time, scalable sequencing platform. With strong revenue growth, expanding gross margins, multi-year pathway towards scaling profitability and ongoing innovation across applications, the company has the ingredients for significant value creation. The current valuation provides a reasonable entry point for long-term investors prepared to look through near-term volatility. Oxford Nanopore Technologies PLC is therefore rated a Buy. We view the company as one of the most differentiated and exciting platforms in the global life sciences tools universe, with multi-year growth potential that should reward patient investors.